Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04806295 · ClinicalTrials.gov registry record
The Leukemia and Lymphoma Society (LLS) National Research Registry
A clinical trial of Blood Cancer, sponsored by Blood Cancer United.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 1
- Study location
NCT04806295: Recruiting study of Blood Cancer, sponsored by Blood Cancer United.
NCT04806295 is a study of Blood Cancer that is actively recruiting participants, run by Blood Cancer United. The registered enrollment target is 1,000 participants, above the 182-participant average among 12 other Blood Cancer trials with a reported enrollment target (449% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04806295, a study of Blood Cancer, is actively recruiting participants, sponsored by Blood Cancer United.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The Leukemia and Lymphoma Society (LLS) has built a National Research Registry to evaluate real world experiences and medical outcomes for people with blood cancer, before, during, and after blood cancer treatments.
Primary Outcome
. The LLS National Research Registry will collect data on up to 1000 research subjects, over up to 10 years, storing that data, including protected health information (PHI) and images, in secure databases, and share de-identified summary data with research partners (like academic researchers, advocacy groups, and pharmaceutical companies) that are advancing treatments for blood cancer. Participation in The LLS National Research Registry may not give research subjects any immediate benefit. It is
Conditions Studied
Interventions
- OTHER any/all treatments for blood cancer
Study Locations (1)
New York
- Lymphoma and Leukemia Society - Rye Brook
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2017-07-24 |
| Est. Completion | 2027-07-23 |
What NCT04806295 shows while recruiting
NCT04806295 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, above the 182-participant average among 12 other Blood Cancer trials with a reported enrollment target (449% higher).
The record links to 1 condition, with Blood Cancer appearing as the primary indexed condition, and to 1 intervention - of which any/all treatments for blood cancer is the first listed.
NCT04806295 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT04806295 about?
NCT04806295 is a clinical study titled "The Leukemia and Lymphoma Society (LLS) National Research Registry". The Leukemia and Lymphoma Society (LLS) has built a National Research Registry to evaluate real world experiences and medical outcomes for people with blood cancer, before, during, and after blood cancer treatments.
What is the current status of trial NCT04806295?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2017-07-24. Estimated completion is 2027-07-23.
What conditions does trial NCT04806295 study?
This clinical trial studies the following conditions: Blood Cancer.
What interventions are being tested in trial NCT04806295?
The interventions under investigation include: any/all treatments for blood cancer (OTHER).
Who is sponsoring clinical trial NCT04806295?
This trial is sponsored by Blood Cancer United, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04806295 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Blood Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04806295's enrollment target sits among peer trials
1,000 2nd of 12 the highest of 12 other Blood Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Blood Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties
RECRUITING · NA
-
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
RECRUITING · Phase 1
-
Take the Reins: The Effects of Nutrient Timing on Cancer-related Fatigue
RECRUITING · Phase 2
-
Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)
RECRUITING · NA
-
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
RECRUITING · NA
-
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI